Tag: bispecific antibody candidates
April 26, 2018
Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017
Merus (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced financial results for the fourth quarter... April 3, 2017